Wed, Dec 24, 2014, 11:15 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Biogen Idec Inc. Message Board

  • Longhauler2007 Longhauler2007 Feb 4, 1999 1:27 PM Flag

    Zero notes

    Can anyone explain why issuing zero convertible notes is a good thing when you could sell more shares to raise cash vs incurring debt?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sometime the useless information is the most interesting.

    • The letter "C" probably stands for "Chimeric". In
      this case half mouse half human.

      The number 2
      probably is the orignial microplate number that harbored
      the original cell that was used to propagate the cell
      line that gave rise to C2B8. Each microplate has
      ninety six wells,12 columns and eight rows. Each column
      has an assigned number( 1 through 12) and each row
      has an assigned letter (A throught H). So the
      original well on the microplate that had the original cell
      that gave rise to the cell line for making antibody
      was located in row B column 8. So now we have
      Chimeric;plate #2;row B column 8.

      Hey I full of all
      kinds of useless information

    • Then you may want to rummage through old annual
      reports for idph to get clues on how the deal was done.
      But companies don't exactly have to tell the truth,
      the whole truth, and nothing but the truth on these
      deals.

    • I'm trying to get a handle on how a company
      forges an agreement to market a drug and Rituxan is very
      similar (monoclonal antibody used to fight cancer) in
      nature to another drug that is building up to this point
      - and eventual FDA approval.

      Rituxan
      (C2B8):
      Rituxan, previously know as the C2B8 antibody, is a
      single-agent monoclonal antibody therapy for the treatment of
      relapsed or refractory low-grade or follicular,
      CD20-positive B-cell non-Hodgkin's lymphoma.

      Campath-1H
      (LDP-03):
      LDP-03, is a humanized monoclonal antibody to the
      leukocyte antigen CAMPATH, which is for the treatment of
      chronic lymphocytic leukemia ("CLL"). LDP-03 combats CLL
      by selectively depleting lymphocytes while sparing
      hematopoietic stem cells.

      This selective depletion
      permits the body to retain needed hematopoietic stem
      cells that are the precursors to, and repopulate the
      blood with, leukocytes and preserve normal immune
      function. LDP-03 binds to the antigen CD52, which is
      expressed almost exclusively on lymphocytes and which is
      not expressed on hematopoietic stem cells, and
      destroys the lymphocytes.

      By attacking the antigen
      CD52 and its lymphocytes, LDP-03 is more selective
      than currently approved drugs for lymphomas and
      leukemias which indiscriminately deplete rapidly-dividing
      cells, including both lymphocytes and hematopoietic stem
      cells.

    • IDEC Corporation manufactures products that
      simplify interaction between humans and machines.


      With a comprehensive line of products, from relays and
      switches to sensors and micro PLCs, IDEC provides critical
      solutions for industrial equipment manufacturers as well as
      advanced technical applications.

      From its
      international headquarters in Sunnyvale, California, IDEC has
      served customers throughout the world for over 23 years.

    • They met or came close to the goal mentioned in
      the press release, of shipping within 3 weeks of
      approval. I didn't happen to have kept a copy of that
      announcement, but like you I remember seeing it.

    • And here I thought he wanted IDEC Pharmaceuticals.

    • I believe that IDEC and/or Genentech started shipping Rituxan to clinicians in Dec. of 1997. I'm not absolutely certain about that, but I know it was very soon following approval.

    • IDEC does have a web page. Bob: I can't believe you missed that one! :-)

      http://www.idec.com

    • I don't think IDEC has a webpage. Considerable
      info is available on the Genentech webpage,
      particularly the "full prescribing information", aka the
      "package insert" that comes with the product at the
      pharmacy.
      http://www.gene.com/Medicines/rituxan_insert.html

      Of course, that is medical information. Details on
      chemistry, how it works (to the extent they know),
      indications, warnings, adverse events, etc. What information
      are you looking for?

    • View More Messages
 
BIIB
340.885+5.125(+1.53%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.